crossover randomized trial

S003060

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)S003060

Design

Randomized: 22
Start year
Treatment: 0.14 weeks
Countries: Germany (1 sites)
Sponsor: Sanofi (industry)
Eligibility: type 2 diabetes on metformin or lifestyle only

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: completers
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Placebo Placebo	metformin or lifestyle; lifestyle: not reported	22	20
A2	lixisenatide Lixisenatide 20 ug single dose	metformin or lifestyle; lifestyle: not reported	22	20

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	mean (years)	54.6
bmi	mean (kg/m2)	29.9
female	n	9
hba1c	max (percent)	8.0
hba1c	mean (percent)	6.9
hba1c	min (percent)	6.2
hba1c	sd (percent)	0.5
weight	mean (kg)	88.7